BR0215016A - Piridoquinoxalinas antivirìcas - Google Patents
Piridoquinoxalinas antivirìcasInfo
- Publication number
- BR0215016A BR0215016A BR0215016-6A BR0215016A BR0215016A BR 0215016 A BR0215016 A BR 0215016A BR 0215016 A BR0215016 A BR 0215016A BR 0215016 A BR0215016 A BR 0215016A
- Authority
- BR
- Brazil
- Prior art keywords
- pyridoquinoxalines
- antiviral
- compounds
- useful
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
^PIRIDOQUINOXALINAS ANTIVIRìCAS". A presente invenção proporciona um composto de fórmula I ou um seu sal farmaceuticamente aceitável em que R^ 1^, R^ 2^ e R^ 3^ são como definido na especificação. Os compostos são úteis para o tratamento de infecções víricas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34287601P | 2001-12-20 | 2001-12-20 | |
PCT/US2002/037613 WO2003053971A1 (en) | 2001-12-20 | 2002-12-19 | Pyridoquinoxaline antivirals |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0215016A true BR0215016A (pt) | 2004-11-09 |
Family
ID=23343656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0215016-6A BR0215016A (pt) | 2001-12-20 | 2002-12-19 | Piridoquinoxalinas antivirìcas |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030207877A1 (pt) |
EP (1) | EP1458719A1 (pt) |
JP (1) | JP2005530681A (pt) |
AR (1) | AR037940A1 (pt) |
AU (1) | AU2002350244A1 (pt) |
BR (1) | BR0215016A (pt) |
CA (1) | CA2471089A1 (pt) |
MX (1) | MXPA04006041A (pt) |
TW (1) | TW200301703A (pt) |
WO (1) | WO2003053971A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040176366A1 (en) * | 2002-08-30 | 2004-09-09 | Wathen Michael W | Method of preventing or treating atherosclerosis or restenosis |
EP2593439B1 (en) | 2010-07-16 | 2016-08-17 | AbbVie Bahamas Ltd. | Process for preparing antiviral compounds |
SG187103A1 (en) | 2010-07-16 | 2013-02-28 | Abbvie Inc | Phosphine ligands for catalytic reactions |
US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
ES2425379T3 (es) * | 2010-08-30 | 2013-10-15 | Saltigo Gmbh | Procedimiento para la preparación de (S)-3-N-metilamino-1-(2-tienil)-1-propanol |
CA2888485C (en) | 2012-10-16 | 2021-01-26 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror.gamma.t |
ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
CN105209453B (zh) | 2012-10-16 | 2017-06-20 | 詹森药业有限公司 | ROR‑γ‑T的亚甲基连接的喹啉基调节剂 |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9624225B2 (en) | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
EP3849979A1 (en) | 2018-09-12 | 2021-07-21 | Novartis AG | Antiviral pyridopyrazinedione compounds |
US11667613B2 (en) | 2019-09-26 | 2023-06-06 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792774A (en) * | 1996-02-21 | 1998-08-11 | Chiroscience Limited | Quinolones and their therapeutic use |
PL341364A1 (en) * | 1997-12-22 | 2001-04-09 | Upjohn Co | 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents |
US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
TW500724B (en) * | 1999-10-05 | 2002-09-01 | Pharmacia & Amp Upjohn Company | Oxazinoquinolones useful for the treatment of viral infections |
US6624159B2 (en) * | 2000-07-12 | 2003-09-23 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6686356B2 (en) * | 2001-12-20 | 2004-02-03 | Pharmacia & Upjohn Company | Pyridoquinoxaline antivirals |
-
2002
- 2002-12-19 BR BR0215016-6A patent/BR0215016A/pt not_active IP Right Cessation
- 2002-12-19 CA CA002471089A patent/CA2471089A1/en not_active Abandoned
- 2002-12-19 WO PCT/US2002/037613 patent/WO2003053971A1/en not_active Application Discontinuation
- 2002-12-19 EP EP02786775A patent/EP1458719A1/en not_active Withdrawn
- 2002-12-19 US US10/326,036 patent/US20030207877A1/en not_active Abandoned
- 2002-12-19 JP JP2003554687A patent/JP2005530681A/ja active Pending
- 2002-12-19 AR ARP020105027A patent/AR037940A1/es not_active Application Discontinuation
- 2002-12-19 AU AU2002350244A patent/AU2002350244A1/en not_active Abandoned
- 2002-12-19 MX MXPA04006041A patent/MXPA04006041A/es unknown
- 2002-12-20 TW TW091136802A patent/TW200301703A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005530681A (ja) | 2005-10-13 |
EP1458719A1 (en) | 2004-09-22 |
TW200301703A (en) | 2003-07-16 |
CA2471089A1 (en) | 2003-07-03 |
WO2003053971A8 (en) | 2004-01-29 |
AU2002350244A8 (en) | 2003-07-09 |
AR037940A1 (es) | 2004-12-22 |
MXPA04006041A (es) | 2004-09-27 |
AU2002350244A1 (en) | 2003-07-09 |
US20030207877A1 (en) | 2003-11-06 |
WO2003053971A1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0215016A (pt) | Piridoquinoxalinas antivirìcas | |
BR0205889A (pt) | Pirazolopirimidinas como agentes tepapêuticos | |
BR0305258A (pt) | Inibidores de polimerase de ns5b de hcv | |
BRPI0411900A (pt) | compostos antivirais e métodos | |
BR0213233A (pt) | Alcinos inibidores de metaloproteinase de matriz | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
ES2160046A1 (es) | Derivados pentapeptidicos. | |
BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
BR0316407A (pt) | Derivados de nucleosìdeo antiviral | |
BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
BRPI0406926A (pt) | Inibidores de polimerase viral | |
BR0008840A (pt) | Derivados de camptotecina tendo atividade antitumoral | |
BRPI0116967B8 (pt) | derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste | |
BR0215067A (pt) | Piridoquinoxalinas antivirais | |
BR0111569A (pt) | Agentes antivirais de imidazopiridina e imidazopirimidina | |
BR0002515A (pt) | Derivados de 4-arilpiperidina para o tratamento do prurido | |
BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BR0210028A (pt) | Agentes antibacterianos | |
BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
BR0113590A (pt) | 7-oxo-piridopirimidinas | |
BR0206501A (pt) | Inibidores de cruzipaìna e outras cisteìna proteases | |
BR0212069A (pt) | Agentes antidiabéticos orais | |
BR0011121A (pt) | Compostos antibacterianos | |
BR0210531A (pt) | Derivados de ácido sulfÈnico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010. |